Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Short-term treatment of hypertension when oral therapy is not feasible or desirable,Management of severe hypertension (off-label)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Extensively metabolized in the liver via cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C8, to inactive metabolites.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
>95% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
92-98% bound primarily to albumin.
8.4 L/kg (0.084 L/kg for a 70 kg adult? Please check: typical Vd is 8.4 L/kg? Actually nicardipine Vd is about 8.4 L/kg, which is large, indicating extensive tissue distribution). Correct: Vd = 8.4 L/kg (range 0.6-8.4 L/kg? Standard value is ~8.4 L/kg).
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral: 35% (extensive first-pass metabolism); intravenous: 100%.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
Cr Cl 30-50 m L/min: maximum IV infusion rate 8 mg/hour; Cr Cl <30 m L/min: maximum IV infusion rate 5 mg/hour. Oral: no adjustment specified but monitor closely.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Child-Pugh Class A: start with 50% of usual dose; Class B: start with 25% of usual dose; Class C: avoid use or use extreme caution.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Limited data; for IV infusion, start at 0.5 mcg/kg/min and titrate to effect; typical range 0.5-5 mcg/kg/min. Oral: 0.5-1 mg/kg/dose three times daily (max 30 mg/dose).
Safety and efficacy not established; use is not recommended in pediatric patients.
Start at lower end of dosing range; IV infusion initial rate 3 mg/hour; oral initial dose 20 mg twice daily; monitor blood pressure closely.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None
No FDA black box warning.
Use caution in patients with coronary artery disease due to risk of increased angina or myocardial infarction,May cause hypotension, hepatic impairment, and elevated liver enzymes,May exacerbate congestive heart failure,Use with caution in patients with impaired renal function,Monitor blood pressure and heart rate during infusion
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to nicardipine or any component of the formulation,Advanced aortic stenosis (may reduce coronary perfusion),Lactation (use not recommended)
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Grapefruit and grapefruit juice may increase nicardipine levels; avoid concurrent use. No other significant food interactions. Maintain a heart-healthy, low-sodium diet as recommended for hypertension management.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no adequate controlled studies; first trimester: potential for teratogenic risk (class C). Second and third trimesters: may cause fetal hypoxia, metabolic acidosis, and hypotension due to maternal hypotension. Use only if benefit outweighs risk.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
NICARDIPINE is excreted in human milk. M/P ratio not reported. Limited data suggest low concentrations; however, potential for adverse effects in infant. Caution advised; consider alternative if possible.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
No specific dose adjustment guidelines for pregnancy; however, increased clearance and volume of distribution in pregnancy may necessitate higher doses. Start with lowest effective dose; titrate carefully to avoid maternal hypotension and fetal distress.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
Cardene (nicardipine) IV infusion in D5W is a dihydropyridine calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. It is photosensitive; protect from light. Administer via central line due to peripheral vein irritation. Titrate based on blood pressure response; onset within minutes. Use with caution in patients with severe aortic stenosis, heart failure, or hepatic impairment. Avoid in patients with advanced aortic stenosis due to risk of reducing coronary perfusion.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
This medication is given intravenously to lower blood pressure quickly.,Your blood pressure and heart rate will be monitored closely during infusion.,Report any pain, redness, or swelling at the IV site immediately.,Avoid sudden position changes to prevent dizziness or fainting.,Do not stop the infusion without medical guidance.,Inform your healthcare provider if you have liver disease, heart failure, or aortic stenosis.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs ADALAT CC, answered by our medical review team.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is a Calcium Channel Blocker that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is: Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER is classified as Category C. NICARDIPINE (CARDENE) is a calcium channel blocker. Animal studies (rats, rabbits) showed embryotoxicity, fetotoxicity, and teratogenicity at doses ≥10× human dose. In humans, no a. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.